Tetrahydrobiopterin and Its Multiple Roles in Neuropsychological Disorders

Midhun, T; Krishna, Sivadas Swathi; Wilson, Samson K

doi:10.1007/s11064-022-03543-x

Cited by 4 publications

(2 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rst synthetic form of BH4 appeared in the 1970s, namely sapropterin, which was approved for the treatment of phenylketonuria in 2007. Common adverse events in patients using sapropterin include headache, rhinorrhea, pharyngitis, vomiting, diarrhea, nasal congestion, cough, and abrasions [27][28][29][30][31][32] . However, little is currently known about the adverse events of pegvaliase in combination with sapropterin.…”

Section: Subgroup Analysesmentioning

confidence: 99%

Adverse events of pegvaliase in the treatment of phenylketonuria: A pharmacovigilance study based on the FAERS database

Liu,

Chen,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Pegvaliase was approved by the FDA in 2018 for the treatment of phenylketonuria(PKU).However, the long-term safety of pegvaliase in a large sample population is unclear. The purpose of this study was to investigate the adverse events associated with pegvaliase in the real world by mining data from the FAERS database. We extract adverse event data on pegvaliase from the FAERS database and perform a disproportionality analysis utilizing ROR，PRR，BCPNN and MGPS. A total of 82 preferred terms (PTs) simultaneously met the criteria of all four algorithms. Common PTs include reactions at the injection site，joint pain, sensitivity reactions, headaches, skin reactions, injection site pruritus, and rash pruritic, corresponding to adverse events reported in clinical trials. Unexpected significant adverse events were identified, such as amino acid level decreased or increased, panic attacks, self-injurious ideation, disturbances in attention, tunnel vision, and so on. The median onset time for adverse events to pegvaliase is 15 days(IQR = 9-42 days), with the majority occurring within 30 days (n=509, 67.78%). The top three drugs most commonly prescribed in conjunction with pegvaliase are famotidine, cetirizine, and sapropterin. When pegvaliase is used in combination with these drugs, it is associated with an increase or decrease in the risk of certain adverse events. Our study provides crucial insights for the safer and more effective use of pegvaliase.

show abstract

Section: Subgroup Analysesmentioning

confidence: 99%

Adverse events of pegvaliase in the treatment of phenylketonuria: A pharmacovigilance study based on the FAERS database

Liu,

Chen,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…It aids in the health of the heart, brain, digestive, and reproductive systems, as well as a variety of physiological activities (Fanet et al, 2017). It plays a role in neurotransmitter production, cardiac and endothelial dysfunction, immunological response (Cai et al, 2005), and other neuropsychological disorders (Midhun et al, 2022). It was shown to be a crucial co-factor for the phenylalanine hydroxylase (PAH) enzyme, which converts phenylalanine to tyrosine.…”

Section: Introductionmentioning

confidence: 99%

BH4 as a Therapeutic Target for ADHD: Relevance to Neurotransmitters and Stress-Driven Symptoms

Wilson,

Thomas

2023

J Atten Disord

Self Cite

View full text Add to dashboard Cite

Tetrahydrobiopterin (BH4) is a critical cofactor in a variety of metabolic pathways that have been linked to ADHD. There have been no previous studies utilizing BH4 as a supplement for ADHD. BH4 has been approved as a treatment for phenylketonuria (PKU). Individuals with PKU and ADHD appear to have low DA levels in common, suggesting that the hypodopaminergic state seen in both illnesses could be a relationship between the two. Clinical research involving supplementation of BH4 has shown low occurrence of adverse. In experiments, BH4 has also been found to have good blood-brain barrier permeability. BH4 also has the ability in scavenging ROS activity, which is an implication of stress and is seen in ADHD. BH4’s significance in ADHD is reviewed in this paper because of its involvement in numerous neurodevelopmental metabolic pathways, and we anticipate that exogenous BH4 can be used to treat ADHD.

show abstract

Computational modeling of neuronal nitric oxide synthase biochemical pathway: A mechanistic analysis of tetrahydrobiopterin and oxidative stress

Allboani,

Kar,

Kavdia

2024

Free Radical Biology and Medicine

View full text Add to dashboard Cite

Tetrahydrobiopterin and Its Multiple Roles in Neuropsychological Disorders

Cited by 4 publications

References 75 publications

Adverse events of pegvaliase in the treatment of phenylketonuria: A pharmacovigilance study based on the FAERS database

Adverse events of pegvaliase in the treatment of phenylketonuria: A pharmacovigilance study based on the FAERS database

BH4 as a Therapeutic Target for ADHD: Relevance to Neurotransmitters and Stress-Driven Symptoms

Computational modeling of neuronal nitric oxide synthase biochemical pathway: A mechanistic analysis of tetrahydrobiopterin and oxidative stress

Contact Info

Product

Resources

About